Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMYXQBF)

Drug Name

CEP-37251 Drug Info

Synonyms

ART-010; EGX-010; OVP (bone loss), Peptech; Osteoprotegerin variant protein (bone loss), Arana; Osteoprotegerin variant protein (bone loss), EvoGenix; Osteoprotegerin variant protein (bone loss), Peptech

Indication

Disease Entry	ICD 11	Status	REF
Bone metastases	2D50	Phase 1	[1]

Cross-matching ID

TTD Drug ID: DMYXQBF

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Osteoclast differentiation factor (ODF)	TT9E8HR	TNF11_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Osteoclast differentiation factor (ODF)	DTT	TNFSF11	3.733	2.868	3.807	3.53

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Bone metastases

ICD Disease Classification

2D50

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Osteoclast differentiation factor (ODF)	DTT	TNFSF11	6.42E-01	-0.16	-0.37

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT01159873) Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women. U.S. National Institutes of Health.
2	This week in therapeutics Cancer. SciBX 3(40); doi:10.1038/scibx.2010.1202. Oct. 14, 2010